Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response - PubMed (original) (raw)
Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response
A Bolmstedt et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul.
Abstract
One of the functions of N-linked glycans of viral glycoproteins is protecting otherwise accessible neutralization epitopes of the viral envelope from neutralizing antibodies. The aim of the present study was to explore the possibility to obtain a more broadly neutralizing immune response by immunizing guinea pigs with gp160 depleted of three N-linked glycans in the CD4-binding domain by site-directed mutagenesis. Mutant and wild type gp160 were formulated into immunostimulating complexes and injected s.c. into guinea pigs. Both preparations induced high serum antibody response to native gp120 and V3 peptides. Both preparations also induced antibodies that bound equally well to the V3 loop or the CD4-binding region, as determined by a competitive enzyme-linked immunosorbent assay (ELISA). The sera from animals, immunized with mutated glycoprotein, did not neutralize nonrelated HIV strains better than did sera from animals, immunized with wild type glycoprotein. Instead, a pattern of preferred homologous neutralization was observed, i.e., sera from animals, immunized with mutant gp160, neutralized mutant virus better than wild type virus, and vice versa. These data indicated that elimination of the three N-linked glycans from gp160 resulted in an altered local antigenic conformation but did not uncover hidden neutralization epitopes, broadening the immune response.
Similar articles
- HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L, Nara P, Dunlop N, Putney S, Morein B. Akerblom L, et al. Biotechnol Ther. 1993;4(3-4):145-61. Biotechnol Ther. 1993. PMID: 8292967 - Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al. Graham BS, et al. J Infect Dis. 1993 Mar;167(3):533-7. doi: 10.1093/infdis/167.3.533. J Infect Dis. 1993. PMID: 8095059 Clinical Trial. - How antibodies block HIV infection: paths to an AIDS vaccine.
Putney S. Putney S. Trends Biochem Sci. 1992 May;17(5):191-6. doi: 10.1016/0968-0004(92)90265-b. Trends Biochem Sci. 1992. PMID: 1350693 Review. - Human studies in the development of human immunodeficiency virus vaccines.
Dolin R. Dolin R. J Infect Dis. 1995 Nov;172(5):1175-83. doi: 10.1093/infdis/172.5.1175. J Infect Dis. 1995. PMID: 7594651 Review.
Cited by
- Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.
Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V. Beltran-Pavez C, et al. PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018. PLoS One. 2018. PMID: 30566493 Free PMC article. - Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
Rathore U, Saha P, Kesavardhana S, Kumar AA, Datta R, Devanarayanan S, Das R, Mascola JR, Varadarajan R. Rathore U, et al. J Biol Chem. 2017 Jun 16;292(24):10197-10219. doi: 10.1074/jbc.M117.788919. Epub 2017 Apr 26. J Biol Chem. 2017. PMID: 28446609 Free PMC article. - Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
Go EP, Ding H, Zhang S, Ringe RP, Nicely N, Hua D, Steinbock RT, Golabek M, Alin J, Alam SM, Cupo A, Haynes BF, Kappes JC, Moore JP, Sodroski JG, Desaire H. Go EP, et al. J Virol. 2017 Apr 13;91(9):e02428-16. doi: 10.1128/JVI.02428-16. Print 2017 May 1. J Virol. 2017. PMID: 28202756 Free PMC article. - Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development.
Sampath S, Carrico C, Janes J, Gurumoorthy S, Gibson C, Melcher M, Chitnis CE, Wang R, Schief WR, Smith JD. Sampath S, et al. PLoS Pathog. 2013;9(6):e1003420. doi: 10.1371/journal.ppat.1003420. Epub 2013 Jun 13. PLoS Pathog. 2013. PMID: 23853575 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials